Compare RNTX & FTHM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RNTX | FTHM |
|---|---|---|
| Founded | 2001 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.9M | 37.9M |
| IPO Year | N/A | 2020 |
| Metric | RNTX | FTHM |
|---|---|---|
| Price | $1.55 | $1.24 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $10.00 | $2.50 |
| AVG Volume (30 Days) | ★ 184.8K | 112.6K |
| Earning Date | 11-14-2025 | 11-11-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $421,612,000.00 |
| Revenue This Year | N/A | $30.07 |
| Revenue Next Year | N/A | $14.66 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 32.78 |
| 52 Week Low | $1.04 | $0.65 |
| 52 Week High | $3.50 | $3.37 |
| Indicator | RNTX | FTHM |
|---|---|---|
| Relative Strength Index (RSI) | 58.01 | 48.02 |
| Support Level | $1.34 | $1.16 |
| Resistance Level | $1.58 | $1.26 |
| Average True Range (ATR) | 0.10 | 0.07 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 87.50 | 47.06 |
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.
Fathom Holdings Inc is a national, technology-driven, real estate services platform integrating residential brokerage, mortgage, title, insurance, and Software as a Service (SaaS) offering to brokerages and agents by leveraging proprietary cloud-based software, intelliAgent. The company has three reportable segments namely Real Estate Brokerage, Mortgage and Technology. The brands of the company include Fathom Realty, Dagley Insurance, Encompass Lending, intelliAgent, LiveBy, Real Results, and Verus Title. Majority of revenue is from Real Estate segment.